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We summarize antimicrobial resistance surveillance
data in human and chicken isolates of Campylobacter.
Isolates were from a sentinel county study from 1989
through 1990 and from nine state health departments par-
ticipating in National Antimicrobial Resistance Monitoring
System for enteric bacteria (NARMS) from 1997 through
2001. None of the 297 C. jejuni or C. coli isolates tested
from 1989 through 1990 was ciprofloxacin-resistant. From
1997 through 2001, a total of 1,553 human Campylobacter
isolates were characterized: 1,471 (95%) were C. jejuni, 63
(4%) were C. coli, and 19 (1%) were other Campylobacter
species. The prevalence of ciprofloxacin-resistant
Campylobacter was 13% (28 of 217) in 1997 and 19% (75
of 384) in 2001; erythromycin resistance was 2% (4 of 217)
in 1997 and 2% (8 of 384) in 2001. Ciprofloxacin-resistant
Campylobacter was isolated from 10% of 180 chicken
products purchased from grocery stores in three states in
1999. Ciprofloxacin resistance has emerged among
Campylobacter since 1990 and has increased in preva-
lence since 1997. 
C
ampylobacter is the most common cause of bacterial
gastroenteritis in the United States, causing an esti-
mated 2.4 million human infections annually (1).
Diagnosed infections have declined in recent years. In
2001, FoodNet surveillance identified 13.4 diagnosed
Campylobacter infections per 100,000 persons (2).
Approximately 95% of diagnosed Campylobacter infec-
tions are due to C. jejuni  (3). Although most Campylo-
bacter infections cause an acute, self-limited illness charac-
terized by diarrhea, fever, and abdominal cramps, severe
infections do occur (4). Antimicrobial treatment can short-
en the duration of illness and may be life-saving in invasive
infections (5–7). Fluoroquinolones (e.g., ciprofloxacin) are
often prescribed empirically for the treatment of gastroen-
teritis and for Campylobacter infections in adults (6,8).
Quinolones (e.g., nalidixic acid), although now seldom
used for treatment in the United States, are frequently used
to screen for fluoroquinolone resistance because of the
close correlation between quinolone and fluoroquinolone
resistance among Campylobacter. Macrolides, such as
erythromycin, are also prescribed to treat Campylobacter
infections (4,9). 
Fluoroquinolone-resistant Campylobacter infections in
humans were first detected in Europe in the late 1980s
(10–12). Subsequently, an increasing proportion of
Campylobacter isolates around the world have been found
to be fluoroquinolone-resistant (13). Studies in the United
States, Europe, and New Zealand have identified poultry
as a principal source of Campylobacter infection (14–16).
Quinolones have been available in human medicine since
the mid-1960s, and the first fluoroquinolone
(ciprofloxacin) was approved for use in humans in 1986.
Two fluoroquinolones, sarafloxacin and enrofloxacin,
were approved for use in poultry by the U.S. Food and
Drug Administration (FDA) in 1995 and 1996, respective-
ly (17). These fluoroquinolones were the first ones
approved in food animals; subsequently, other fluoro-
quinolones have been approved for veterinary use but not
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resistant  Campylobacter in the United States, we
reviewed national surveillance data to determine the
prevalence of antimicrobial resistance, particularly
ciprofloxacin resistance, among Campylobacter isolates;
conducted a case-control study to determine the propor-
tion of ciprofloxacin-resistant infections that were domes-
tically acquired; and performed a retail survey to
determine the prevalence of ciprofloxacin-resistant
Campylobacter contaminating chicken products sold in
selected supermarkets. 
Methods
National Surveillance for Resistance in Campylobacter
1989–1990 Sentinel County Study 
From 1989 to 1990, a national county-based survey of
antimicrobial susceptibility among Campylobacter isolates
was conducted. Sentinel clinical laboratories in 19 coun-
ties participated. The methods of this survey are described
elsewhere (19,20). Briefly, the first five sporadic
Campylobacter isolates identified each month were for-
warded to the Centers for Disease Control and Prevention
(CDC). Patients with Campylobacter infection were inter-
viewed with a standard questionnaire, which included
information about clinical illness and exposures (i.e., food,
animal, and foreign travel) during the 2 weeks before ill-
ness onset. Isolates were determined to be Campylobacter
by dark-field microscopic examination and hippurate
hydrolysis (20–22). Hippurate-positive isolates were con-
sidered C. jejuni. All isolates with questionnaires received
during the first 4 months of the study underwent suscepti-
bility testing. Because of a shortage of reagents, a random
sample of 50% of isolates with completed questionnaires
received during the last 8 months of the study was further
characterized. Isolates were tested for susceptibility to
azithromycin, chloramphenicol, ciprofloxacin, clin-
damycin, erythromycin, gentamicin, nalidixic acid, and
tetracycline by using broth microdilution methods (19). In
2003, a retrospective analysis of the hippurate-negative
isolates was completed; these isolates were speciated by
using methods described below.
National Antimicrobial Resistance Monitoring
System (NARMS), 1997–2001
NARMS for enteric bacteria is a collaboration between
CDC, the Food and Drug Administration, and state and
local health departments. The system monitors patterns of
antimicrobial drug resistance. NARMS methods are
described in detail elsewhere (23). 
In brief, isolates were tested for viability, confirmed as
Campylobacter, and identified to the species level by using
the hippurate hydrolysis test according to published meth-
ods (21,22). Hippurate-negative Campylobacter in which
the hippuricase gene could be detected by polymerase
chain reaction (PCR) were identified as C. jejuni (24).
Isolates that tested negative for the hippuricase gene but
positive for a C. coli-specific ceuE sequence were identi-
fied as C. coli (25). Isolates that could not be identified as
either  C. jejuni or  C. coli by these PCR assays were
referred to the National Campylobacter Reference
Laboratory at CDC for identification with genotypic (e.g.,
16S rRNA sequencing) and phenotypic methods (21). 
Isolates were tested with the E-test system (AB
BIODISK, Solna, Sweden) to determine MICs for six
antimicrobial agents: chloramphenicol, ciprofloxacin, clin-
damycin, erythromycin, nalidixic acid, and tetracycline.
Beginning in 1998, azithromycin and gentamicin were also
included. When available, National Committee for Clinical
Laboratory Standards interpretive criteria for
Enterobacteriaceae MICs were used; ciprofloxacin resist-
ance was defined as MIC >4 µg/mL, and erythromycin
resistance was defined as MIC >8 µg/mL (26). Multidrug
resistance was defined as resistance to two or more of the
original six antimicrobial agents.
We used a multivariable logistic regression model to
assess changes in the proportion of isolates with antimicro-
bial drug resistance from 1997 through 2001 because the
population under surveillance more than doubled from
1997 to 2001, and substantial site-to-site variation in
prevalence of antimicrobial drug resistance was identified
(i.e., uncertainty was found in the denominators for calcu-
lating rates). The model was for antimicrobial drug resist-
ance as a function of year and included main effects
adjustments for age categories and site-to-site variation in
prevalence. Within the available data, site by year interac-
tion was not a significant factor but because the catchment
areas expanded, the hypothesis of site by year interaction
could not be fully tested.
1997 Retrospective Case-Comparison Study
Using NARMS isolates, we conducted a retrospective
case-comparison study in four NARMS sites (California,
Connecticut, Georgia, and Oregon). Persons with
ciprofloxacin-resistant (CipR) Campylobacter infection
identified in 1997 were compared with persons in whom
the diagnosis of ciprofloxacin-sensitive (CipS)
Campylobacter infection was made that same year. We
compared up to two CipS cases for each CipR case and
matched cases by geographic site and date of stool speci-
men collection. All case-patients were interviewed by tele-
phone, usually within 8 weeks of their illness onset, about
demographics, clinical information, and exposures (e.g.,
antimicrobial drug use in the 4 weeks before illness onset,
foreign travel, and consumption of poultry and raw milk in
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tionnaire. 
1999 Retail Survey
Three NARMS-participating state health departments
(Georgia, Maryland, and Minnesota) participated in a sur-
vey of retail chicken products. From January to June 1999,
each site purchased a convenience sample of 10 whole
broiler chickens per month from supermarkets located
within the state. State public health laboratories at each site
tested the samples for Campylobacter. Carcass rinse sam-
ples were centrifuged, and pellets were incubated in
enrichment broth and plated onto Campylobacter blood
agar plates according to methods published elsewhere
(27); neither media contained quinolone or macrolide
antimicrobial agents. Campylobacter isolates were for-
warded to CDC for species identification and antimicro-
bial susceptibility testing according to NARMS methods.
Results
National Surveillance
1989–1990 Sentinel County Study 
Two hundred ninety-eight patients were interviewed,
and their Campylobacter isolates were tested. Of these iso-
lates, 289 (97%) were C. jejuni, 8 (3%) were C. coli, and 1
(0.3%) was a C. lari. None were resistant to ciprofloxacin,
and 3 (1%) of 294 were resistant to nalidixic acid (MIC >
32 µg/mL); 1 isolate was C. lari, which is inherently resist-
ant to nalidixic acid (28), and 2 were C. jejuni. The C. lari
isolate was resistant to ofloxacin (MIC = 8 µg/mL), inter-
mediately resistant to norfloxacin (MIC = 8 µg/mL) but
susceptible to ciprofloxacin (MIC = 2 µg/mL).1 The two
nalidixic acid-resistant C. jejuni isolates were susceptible
to ciprofloxacin (MIC = 0.5 µg/mL) and norfloxacin and
ofloxacin (MIC < 2 µg/mL). The proportion of the isolates
resistant to tetracycline was 42% (124/295). The resistant
proportion for the other antimicrobial agents tested were as
follows: erythromycin 3% (8/295), clindamycin 2%
(6/295), azithromycin 2% (5/294), chloramphenicol 0%
(0/295), and gentamicin 0% (0/295). Travel history was
available for 296 patients with Campylobacter infection;
23 (8%) patients traveled outside of the United States in
the week before illness onset. Of the persons with avail-
able information, 32 (11%) of 295 had taken an antimicro-
bial agent in the 30 days before illness onset, 46 (15%) of
298 were hospitalized, and 241 (81%) of 297 were treated
with an antimicrobial agent for their illness. Among the
234 persons for whom treatment data were available, the
most common agents used for treatment were erythromy-
cin (62%), ciprofloxacin (19%), and trimethoprim-sul-
famethoxazole (5%). Of the three patients with nalidixic
acid-resistant infections, none traveled outside the United
States, and none were treated with a quinolone or fluoro-
quinolone in the month before illness.
NARMS, 1997–2001
From 1997 to 2001, a total of 1,932 presumptive
Campylobacter isolates were received at CDC through
NARMS; 193 (10%) were excluded because they were not
viable, 104 (5%) were not in accordance with the one-a-
week sampling method, 39 (2%) were determined not to be
Campylobacter, 22 (1%) were duplicates, and 21 (1%)
were contaminated cultures. Of the 1,553 (80%) isolates
further characterized and included in this analysis, 1,471
(95%) were C. jejuni, 63 (4%) were C. coli, 7 (0.4%) were
C. upsaliensis, 5 (0.3%) were C. fetus, 2 (0.1%) were C.
lari, and 5 (0.3%) were undetermined (i.e., determination
by 16S study did not identify a species). Forty-five percent
of case-patients were female; the median age was 33 years
(range <1–96). Among 1,439 isolates with known source
of specimen collection, 1,426 (99%) were from stool sam-
ples, and 13 (1%) were from blood samples. Among blood
isolates, eight were C. jejuni, two were C. fetus, two were
C. upsaliensis, and one was C. lari. 
The results of susceptibility testing among
Campylobacter isolates by species are shown in Table 1.
Resistance to ciprofloxacin among all Campylobacter iso-
lates was 13% in 1997 and 19% in 2001. Resistance to
erythromycin among all Campylobacter isolates was 2%
in 1997 and 2% in 2001. The results of antimicrobial sus-
ceptibility testing by year for isolates of the most common
species, C. jejuni, are shown in Table 2
The prevalence of ciprofloxacin-resistant Campylo-
bacter ranged from 0% (0/14) in Tennessee in 1999 to 26%
(14/53) in Georgia in 2001. By using a multivariate logis-
tic regression model and controlling for age and site-to-site
variation in prevalence, the proportion of all
Campylobacter isolates resistant to ciprofloxacin and
nalidixic acid in 2001 was significantly higher than the
proportion of isolates resistant to ciprofloxacin in 1997
(data only shown for ciprofloxacin in Table 3). The
remaining antimicrobial drugs had no statistically signifi-
cant change in resistance over time (data not shown). 
Fifty-one percent of Campylobacter isolates were
resistant to >1 drug, 18% were resistant to >2 drugs, and
10% were resistant to >3 drugs. The most common mul-
tidrug resistance (i.e., >2 drugs) pattern included
ciprofloxacin, nalidixic acid, and tetracycline.
RESEARCH
1104 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 6, June 2004
1This isolate was reported to be ciprofloxacin resistant in reference
20; more recently established interpretive criteria define it as sus-
ceptible.1997 Retrospective Case-Comparison Study
Sixteen (57%) of 28 ciprofloxacin-resistant Campylo-
bacter (CipR) case-patients and 31 ciprofloxacin-sensitive
(CipS) case-patients were interviewed. The median age
was 46 years (range 9–76 years) for CipR patients and 24
years (range 1–87 years) for CipS patients (Wilcoxon
rank-sum, p = 0.08). CipR patients did not differ signifi-
cantly from CipS patients in terms of sex (40% vs. 42%
female, p = 0.1), race (87% vs. 77% white, p = 0.08), and
place of residence (87% vs. 61% urban/suburban areas, p
= 0.06). Five (31%) CipR patients were hospitalized for
gastroenteritis compared with 1 (3%) CipS patient
(matched odds ratio [mOR] = 13.6, 95% confidence inter-
val [CI] 1.4 to 130.1). Eight (57%) CipR case-patients
reported having bloody diarrhea compared with eight
(30%) CipS patients (mOR = 3.2, 95% CI 0.8 to 12.1).
Seven (44%) of 16 CipR patients compared with 1 (3%) of
31 CipS patients traveled to a foreign country in the 7 days
before illness onset (mOR = 23.3, 95% CI 2.5 to 215.6); 5
(71%) of 7 CipR patients traveled to Europe while 1 CipS
patient traveled to the Caribbean. Among all case-patients,
35 of 47 reported treatment with an antimicrobial agent for
their illness. Of those who recalled the name of the antimi-
crobial drug, 75% reported taking a fluoroquinolone, 16%
reported taking a macrolide, and 8% took trimethoprim-
sulfamethoxazole (TMP/SMX). One CipR patient and one
CipS patient took fluoroquinolones between onset of ill-
ness and collection of stool specimens. Among the eight
CipR patients who did not travel and did not take fluoro-
quinolones between illness onset and stool specimen col-
lection, seven (87%) consumed poultry in the 7 days
before infection; this finding was not statistically different
from that in CipS patients. No other exposures were signif-
icantly associated with ciprofloxacin-resistant infection,
including having pets, drinking raw milk, or being exposed
to a farm (data not shown). 
1999 Retail Survey 
Among the 180 retail chicken products purchased, rep-
resenting 18 domestic brand names from 22 grocery stores,
Campylobacter  was isolated from 80 (44%) samples.
Sixty-two (77%) were C. jejuni, 16 (20%) were C. coli,
and 2 (2%) were undetermined (i.e., determination by 16S
study did not identify a species). The prevalence of
Campylobacter isolated was 33% (20 of 60) in Georgia,
37% (22 of 60) in Maryland, and 63% (38 of 60) in
Minnesota. This difference among sites was in part due to
the difference in isolation rates of C. coli; 14 (87%) of the
Antimicrobial-resistant Campylobacter
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Table 1. Antimicrobial resistance among Campylobacter isolates by species, National Antimicrobial Resistance Monitoring System  
1997–2001 
  % resistant 
Antimicrobial agent 
C. jejuni  
(n = 1,471) 
C. coli  
(n = 63) 
C. upsaliensis  
(n = 7) 
C. lari  
(n = 2) 
C. fetus  
(n = 5) 
Undetermined
a  
(n = 5 ) 
Total  
(n = 1,553) 
Azithromycin
b  2  9  0  0  0  0  2 
Chloramphenicol  0.3  5  0  0  0  40  0.6 
Ciprofloxacin  16  30
c  14  0  0  0  16 
Clindamycin  1  9  0  0  0  20  2 
Erythromycin  2  8  0  0  0  20  2 
Gentamicin
b   0  2  0  0  0  0  0.1 
Nalidixic acid  17  36
c  14  100  80  20  18 
Tetracycline  43  43  0  0  20  0  43 
aUndetermined isolates were hippurate-negative Campylobacter that could not be further speciated with available polymerase chain reaction primers. 
bFor azithromycin and gentamicin, only 1,336 isolates were tested. 
cComparison of proportion of resistant C. coli to resistant C. jejuni was statistically significant for ciprofloxacin and nalidixic acid but not tetracycline (p < 
0.01) 








(n = 209) 
1998  
(n = 297) 
1999  
(n = 294) 
2000  
(n = 306) 
2001  
(n = 365) 
Total  
(n = 1,757) 
Azithromycin
c  1  –  1  3  2  2  1 
Chloramphenicol  0  1  1  0.3  0  0  0.3 
Ciprofloxacin  0  12  14  18  14  18  13 
Clindamycin  1  1  1  1  1  2  1 
Erythromycin  1  1  2  2  1  2  2 
Gentamicin
c  0  –  0  0  0  0  0 
Nalidixic acid  1  13  16  20  16  19  14 
Tetracycline  42  47  46  46  39  40  43 
a1989–1990 U.S. sentinel county study used different sampling and laboratory methods (microbroth dilution testing) than NARMS (Etest). However, 
studies have concluded that broth microdilution and Etest give equivalent results for ciprofloxacin susceptibility testing of Campylobacter (44).  
bIn 1989–1990 U.S. county study, only 285 isolates were tested for azithromycin and nalidixic acid susceptibility. 
cFor azithromycin and gentamicin, only isolates received between 1998 and 2001 were tested (N = 1,262). 16 C. coli isolates came from retail chickens purchased in
Minnesota. A ciprofloxacin-resistant strain of Campylo-
bacter was identified in 10% of the 180 retail chicken
products tested, and an erythromycin-resistant strain was
identified in 2% of chicken products (Table 4). The distri-
bution of ciprofloxacin MICs in Campylobacter species of
retail chicken and human isolates was similar. For both
human and poultry Campylobacter isolates, MICs were
predominantly <0.5 or >32 µg/mL with few intermediate
phenotypes (Figure 1).
Discussion
Fluoroquinolone-resistant  Campylobacter  have
emerged over the last decade in the United States. In 1990,
no ciprofloxacin-resistant human isolates were identified
in a national sentinel county-based survey. From 1997 to
2001, the prevalence of ciprofloxacin-resistant
Campylobacter increased significantly from 13% to 19%.
These data are consistent with four prior surveillance stud-
ies from humans conducted in the United States: 1) a hos-
pital-based study in Pennsylvania conducted from 1982 to
1991 found no fluoroquinolone resistance among C. jejuni
isolates (29), 2) a second study at the same Pennsylvania
hospital found a sharp increase in ciprofloxacin resistance
among C. jejuni from 8% in 1996 to 40% in 2001 (30), 3)
a study conducted in Wisconsin between 1992 and 1995
found 12% of the C. jejuni to be ciprofloxacin-resistant
(31), and 4) a study in Minnesota showed an increase in
quinolone-resistant C. jejuni isolates from 1.3% in 1992 to
10.2% in 1998 (Figure 2) (18). The emergence of fluoro-
quinolone resistance among Campylobacter isolates in the
1990s has occurred while resistance to other antimicrobial
agents has remained stable. Specifically, resistance to the
macrolides, azithromycin and erythromycin, which are
commonly used antimicrobial agents in humans (32), has
remained low (1%–3%). 
Our retrospective case-comparison study showed that
patients with ciprofloxacin-resistant C. jejuni infections
were more likely to be hospitalized compared to patients
with ciprofloxacin-susceptible infections. These results,
however, are based on a small number of patients, and age
could have been a confounder. Other studies have found
that patients infected with fluoroquinolone-resistant
Campylobacter have a longer duration of diarrhea than
patients with fluoroquinolone-susceptible isolates,
although no difference in hospitalization rates have been
reported (18,33). These findings may have clinical impli-
cations. Ciprofloxacin is commonly used to treatment
severe  Campylobacter infections and other intestinal
infections in adults, so the rise of fluoroquinolone resist-
ance may result in ineffective treatment when fluoro-
quinolones are used. Macrolides, which are efficacious in
treating Campylobacter (5,34), should still be considered
the first-line drugs for severe Campylobacter infections, as
resistance to this class remains low.
Our study also identified foreign travel, particularly to
Europe, to be associated with ciprofloxacin-resistant C.
jejuni  infection. High rates of fluoroquinolone-resistant
Campylobacter have been reported from southern Europe
and other regions of the world (13). Studies in northern
Europe have associated fluoroquinolone use in food ani-
mals, particularly poultry, as a source for human infection
with fluoroquinolone-resistant Campylobacter  (13).
Nevertheless, while foreign travel was a risk factor in our
study, over half of the ciprofloxacin-resistant infections
were domestically acquired. Ciprofloxacin resistance was
not associated with use of fluoroquinolones before speci-
men collection, which suggests that fluoroquinolone-
resistant organisms did not result from individual use of
fluoroquinolones. A more recent, larger case-control study
of patients infected with ciprofloxacin-resistant Campylo-
bacter infections found similar results to our study; 58% of
illnesses were domestically acquired, and none of the
patients took fluoroquinolones after illness onset and
before specimen collection (35). 
Our 1999 survey of retail chicken sold in selected
supermarkets provided ecologic evidence that chicken
RESEARCH
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Table 3. Trend analysis of the proportion of fluoroquinolone-
resistance among Campylobacter, National Antimicrobial 
Resistance Monitoring System, 1997–2001 
Y  Unadjusted OR
a (95% CI)  Adjusted OR
b (95% CI) 
1997
c  1.0  1.0 
1998  1.0 (0.6 to 1.7)  1.3 (0.7 to 2.4) 
1999  1.4 (0.9 to 2.3)  2.1 (1.2 to 3.9) 
2000  1.1 (0.7 to 1.8)  1.5 (0.8 to 2.8) 
2001  1.6 (1.0 to 2.5)  2.5 (1.4 to 4.4) 
aOR, odds ratio; CI, confidence interval. 
bAdjusted odds ratios were calculated by using logistic regression model, 
which accounted for site-to-site variation in prevalence. 
c1997 was the reference value. 
Table 4. Antimicrobial resistance among Campylobacter isolates 
from retail chicken, by species, National Antimicrobial Resistance 
Monitoring System, 1999 
% resistant 
Antimicrobial agent 
C. jejuni  
(n = 62) 
C. coli  
(n = 16) 
Other
a  
(n = 2) 
Azithromycin  6  0  0 
Chloramphenicol  0  0  50 
Ciprofloxacin  24  19  50 
Clindamycin  5  0  0 
Erythromycin  6  0  0 
Gentamicin  0  6  0 
Nalidixic acid  29  37  50 
Tetracycline  69  50  50 
aOne isolate was undetermined (i.e., hippurate-negative Campylobacter 
that could not be further speciated by 16S polymerase chain reaction 
study), and one isolate was an unknown Campylobacter that could not be 
further characterized. may be a source of domestically acquired ciprofloxacin-
resistant Campylobacter infections; 10% of retail chickens
were contaminated with ciprofloxacin-resistant Campylo-
bacter. Other studies have shown that Campylobacter,
including ciprofloxacin-resistant Campylobacter, are com-
monly isolated from retail poultry meats. Asurvey of retail
meats purchased in the Washington, D.C., area isolated
Campylobacter species from 71% of chicken and 14% of
turkeys tested; (36) 25% of the C. jejuni isolates and 40%
of the C. coli isolates were resistant to ciprofloxacin (37).
A second survey in Minnesota isolated Campylobacter
from 88% of retail chicken meats purchased in 1997,
including  C. jejuni in 74% and C. coli in 21%.
Ciprofloxacin-resistant  Campylobacter was identified in
20% of retail chicken products (18). In this study, compar-
ison of molecular subtypes from human and retail chicken
quinolone-resistant  C. jejuni isolates found that six of
seven subtypes were indistinguishable from each other. 
In the United States, the FDA has approved the use of
fluoroquinolones at different times for humans and food
animals. Fluoroquinolones have been commonly used in
humans for treating intestinal and other infections since
1986 (32). The first fluoroquinolones to be FDA-approved
for use in food animals in the United States were
sarafloxacin in 1995 and enrofloxacin in 1996. These flu-
oroquinolones were approved for use in chickens and
turkeys to treat bacterial respiratory infections principally
caused by E. coli. These agents are typically administered
to the entire poultry house (often >20,000 birds) through
drinking water, which results in the treatment of sick and
healthy birds with various concentrations of fluoro-
quinolones. The extent of fluoroquinolone use in chickens
and turkeys in the United States is not known; manufactur-
ers and farmers are not required to report these data. The
Animal Health Institute has estimated that 1%–2% of the
approximately 8 billion broiler chickens slaughtered each
year in the United States are treated with fluoroquinolones
(38). An experiment with Campylobacter-infected chick-
ens treated with enrofloxacin and sarafloxacin showed that
ciprofloxacin resistance rapidly developed among
Campylobacter (39). 
An association between the approval of fluoro-
quinolones for use in food-producing animals and the
development of fluoroquinolone-resistant Campylobacter
in animals and humans has been noted in several coun-
tries. The approval of fluoroquinolones for use in food
animals has been followed temporally by a rise in
ciprofloxacin-resistant Campylobacter and other enteric
pathogens isolated from animals and humans in Denmark,
the Netherlands, and Spain (13,40). After the use of oral
fluoroquinolones in pigs was discontinued in Denmark in
1999, nalidixic acid resistance among C.  coli isolates
from pigs decreased from 17% in 1998 to 5% in 2001
(41). In the United States, FDA has recently conducted a
quantitative risk assessment and concluded that fluoro-
quinolone use in chickens and turkeys results each year in
>10,000 human infections with fluoroquinolone-resistant
Campylobacter in persons who seek medical care and are
treated with fluoroquinolones (42). FDA proposed the
withdrawal of approval of fluoroquinolones for use in
poultry in October 2000 (43). This is the first time a pro-
posal has been made to withdraw an approval for an
antimicrobial used in agriculture because of associated
emergence of resistance in humans. The manufacturer of
sarafloxacin has since withdrawn this product from the
market, but the manufacturer of enrofloxacin continues to
Antimicrobial-resistant Campylobacter
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Figure 1. Distribution of ciprofloxacin MICs among Campylobacter
jejuni isolated from humans and retail chicken. A, human  isolates,
1997–2001; N = 1,471. B, grocery store purchased chicken iso-
lates, 1999; N = 62.
Figure 2. Quinolone- and fluoroquinolone-resistant Campylobacter
jejuni in the United States, 1982–2001. FQ, fluoroquinolone; MN,
Minnesota quinolone resistance among C. jejuni strains data
(adapted from 18), NARMS, National Antimicrobial Resistance
Monitoring System. Prior survey data adapted from reference 19
and 30.market enrofloxacin for use in poultry in the United
States.
Our studies had several limitations. The retrospective
case-comparison study did not assess exposures among
travelers and therefore cannot assess the possibility that the
travelers may have acquired ciprofloxacin-resistant
Campylobacter from eating poultry or other foods while
traveling. Routine surveillance for antimicrobial suscepti-
bility among Campylobacter did not start until 1997, and
therefore we cannot identify national trends in antimicro-
bial resistance from 1991 to 1996. Other limitations are
evident in NARMS Campylobacter surveillance, including
the use of sentinel clinical laboratories in some states and
some variation in the isolation procedures. However, these
limitations are not likely to be associated with an increased
(or decreased) likelihood of selecting antimicrobial-resist-
ant isolates for submission to NARMS since the antimicro-
bial resistance pattern of the isolates were not known when
the isolates were selected. Lastly, because NARMS
Campylobacter  surveillance was not nationwide and
resistance may differ regionally, generalization to the U.S.
population should be done with caution.
In summary, we describe the emergence over the last
decade of fluoroquinolone-resistant Campylobacter infec-
tions in the United States. As of 1997, more than half of
such infections were domestically acquired. In 1999, fluo-
roquinolone-resistant  Campylobacter organisms were
present on a substantial fraction of chickens sold at super-
markets in three widely separated locations in the United
States. Continuing national surveillance of human infec-
tions and prospective national monitoring of the frequency
of contamination of poultry at retail would provide useful
ongoing information. Clinicians should include
macrolides, such as azithromycin, as a first-line treatment
of severe Campylobacter infections. 
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